The A2A subtype of adenosine receptors has gained popularity as a target for treating several neurodegenerative diseases, for instance, neuroinflammation, including multiple sclerosis, Parkinson’s and Alzheimer’s disease, and neuropsychiatric disorders [54]. This evidence concerns the gene IGKV2D-29 and early-onset autosomal dominant Alzheimer disease.